Drug Type Bispecific antibody |
Synonyms + [1] |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 2 | CN | 10 Oct 2024 | |
Female Genital Neoplasms | Phase 2 | CN | 06 Aug 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 24 Jul 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 24 Jul 2024 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 01 Jul 2024 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 01 Jul 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 2 | CN | 15 May 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 20 Jan 2023 | |
Triple Negative Breast Cancer | IND Approval | CN | 21 May 2024 | |
Triple Negative Breast Cancer | IND Approval | CN | 21 May 2024 |